Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Continuous flow pumps and total artificial hearts: management issues.

Timothy J Myers1, Kimberly Robertson, Toni Pool

  • 1Cardiovascular Surgical Research Laboratories, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA. tmyers@heart.thi.tmc.edu

The Annals of Thoracic Surgery
|June 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fate of dilated ascending aorta after transcatheter aortic valve replacement.

JTCVS structural and endovascular·2026
Same author

Alternative Polyadenylation Signatures Distinguish Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension: Implications for RNA-Based Diagnostics and Therapeutics.

British journal of biomedical science·2026
Same author

Comparison of Short versus Extended Valganciclovir Prophylaxis in Donor-Positive Recipient-Negative Mismatched Heart Transplant Recipients: An Observational Study.

Clinical transplantation·2025
Same author

Evaluation of warfarin dose and INR time in therapeutic range in left ventricular assist device patients with sleeve gastrectomy.

The International journal of artificial organs·2025
Same author

Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications.

European heart journal·2023
Same author

Comparison of survival by vasoactive-inotropic score in patients receiving veno-arterial extracorporeal life support.

The International journal of artificial organs·2023

Comparing axial flow ventricular assist systems and total artificial hearts (TAH) is crucial for patient care. The Jarvik 2000 axial flow pump and AbioCor TAH differ in function and patient selection criteria.

Area of Science:

  • Cardiovascular Engineering
  • Medical Devices
  • Surgical Technology

Background:

  • Axial flow ventricular assist systems and total artificial hearts (TAH) represent advanced solutions for end-stage heart failure.
  • Axial flow pumps (e.g., Jarvik 2000) provide continuous flow from the left ventricle (LV) to the aorta.
  • TAH devices (e.g., AbioCor) offer pulsatile flow for complete circulatory support.

Purpose of the Study:

  • To compare the Jarvik 2000 axial-flow pump and the AbioCor TAH.
  • To highlight differences in their application, patient selection, and management.
  • To inform clinical decision-making for advanced cardiac support.

Main Methods:

  • Comparative analysis of two distinct cardiac support systems: Jarvik 2000 axial-flow pump and AbioCor TAH.

Related Experiment Videos

  • Review of patient data and outcomes for both devices.
  • Examination of management requirements, including anticoagulation, infection control, and pharmacotherapy.

    • Main Results:

    • The Jarvik 2000 is used for bridge-to-transplantation and destination therapy, with 45 patients receiving support (average 132.8 days).
    • Of 30 bridge-to-transplantation cases, 47% received transplants, 17% continued support, and 37% died.
    • Five of seven AbioCor TAH patients survived post-operatively, with some achieving ambulation and hospital discharge.

    Conclusions:

    • Both Jarvik 2000 and AbioCor TAH require anticoagulation and infection management.
    • Jarvik 2000 patients may need inotropic agents, vasoactive drugs, and pacemaker therapy.
    • AbioCor TAH patients generally do not require medications for heart function support, though vasoactive agents may aid blood pressure control.